Beware Of Krispy Kreme Stock and More
When Pepsi (PEP) shares continued their downtrend in the last week, it suggested a shift in consumer behavior. Krispy Kreme Donuts (DNUT) and Wendy’s Company (WEN) are at the highest risk as inflation and tariffs hurt consumer spending.In the first quarter, Wendy’s posted a 2.1% Y/Y drop in revenue, to $523.5 million. It required opening 68 net new restaurants to target a full-year net unit growth of 2% to 3%. For the year, Wendy’s expects global sales of between negative 2.0% and no growth (0%).Krispy Kreme fared poorly, losing over 35% of its value last week. The company reported weak traffic as consumers shifted their discretionary spending away from unhealthy, sweet foods. In the quarter, the firm lost $0.05 a share. Adjusted EBITDA margin fell to 6.4%, down by 670 basis points from last year. CEO Josh Charlesworth said that the dividend suspension, which previously yielded over 5%, enables Krispy Kreme to preserve its cash. It will pay down its debt and deleverage its balance sheet.Shareholders sold the stock while bears held a 13.6% short interest against DNUT stock.Krispy Kreme has an urgency to eliminate its unproductive stores. It cannot open more stores, exposing its supply to a shrinking customer base. Investors may consider McDonald’s (MCD) instead. Watch Starbucks (SBUX) and Chipotle (CMG) as shares trade lower.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


